Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869932 | 0.87 | TAAR1 (0.35) | HTR1ADRD2HTR2ATAAR1IDO1 | |
| SCHEMBL55137 | 0.82 | HTR1A (0.58) | HTR1ADRD2MAOAMAOBALDH1A1 | |
| SCHEMBL1287474 | 0.78 | CALM1 (0.52) | DRD2HPGDALOX15HSD17B10HTR2A | |
| SCHEMBL10719547 | 0.77 | LIPG (0.34) | HTR2ATAAR1 | |
| SCHEMBL5542565 | 0.76 | HTR1A (0.48) | HTR1ADRD2MAOAMAOBALDH1A1 | |
| SCHEMBL5541602 | 0.76 | HTR1A (0.48) | HTR1ADRD2MAOAMAOBALDH1A1 | |
| SCHEMBL10793973 | 0.76 | HTR1A (0.48) | HTR1ADRD2MAOAMAOBALDH1A1 | |
| Ethylene SCHEMBL7025277 | 0.76 | ALDH1A1 (0.61) | MAOAMAOBALDH1A1HPGDALOX15 | |
| Ethylene SCHEMBL16239286 | 0.76 | ALDH1A1 (0.61) | MAOAMAOBALDH1A1HPGDALOX15 | |
| SCHEMBL9741303 | 0.76 | ALDH1A1 (0.69) | MAOAMAOBALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| CN-111491963-B | Method for producing (meth) acrylic composition, coating material containing (meth) acrylic composition, and cured body | 三菱瓦斯化学株式会社 | 2023-04-28 | — | — | CN | disclosed |
| CN-113710750-B | (meth) acrylic composition, coating material containing same, and cured product | 三菱瓦斯化学株式会社 | 2022-07-12 | — | — | CN | disclosed |
| US-20220145118-A1 | (METH)ACRYLIC COMPOSITION, PAINT AND CURING AGENT COMPRISING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11326073-B1 | (meth)acrylic composition, paint and curing agent comprising same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2022-05-10 | — | — | US | disclosed |
| CN-113710750-A | (meth) acrylic composition, coating material containing same, and cured product | 三菱瓦斯化学株式会社 | 2021-11-26 | — | — | CN | disclosed |
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| CN-108603953-B | Light diffusing agent, light diffusing resin composition, and molded article | 三菱瓦斯化学株式会社 | 2021-08-24 | — | — | CN | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | EpiAxis Therapeutics Pty Ltd. (AU) | 2021-04-29 | — | — | US | disclosed |
| WO-1999013895-A1 | POLYPEPTIDE COMPOSITIONS THAT INHIBIT POTASSIUM CHANNEL ACTIVITY AND USES THEREFOR | UNIVERSITY OF FLORIDA (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998023639-A2 | ShK TOXIN COMPOSITIONS AND METHODS OF USE | UNIVERSITY OF FLORIDA (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5506227-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS | MERCK FROSST CANADA, INC. (CA) | 1996-04-09 | — | — | US | disclosed |
| EP-0639181-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1995-02-22 | — | — | EP | disclosed |
| EP-0636124-A1 | 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021168-A1 | THIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021169-A1 | BENZOTHIAZOLE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021170-A1 | 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993021158-A1 | PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| US-4710454-A | CONTAINING PHOSPHONIC ACID AND POLYACRYLIC DERIVATIVE | AGFA-GEVAERT AKTIENGESELLSCHAFT, A CORP. OF GERMANY (DE) | 1987-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | HTR1A 68/4885DRD2 262/4885MAOA 54/4885 |
| US-20210121496-A1 | METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS | BMI1, KDM1B, KDM6B | HTR1A 4221/4885DRD2 4799/4885MAOA 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.